Legend Biotech Plans $225M ADS Offering to Fuel Expansion
Event summary
- Legend Biotech (NASDAQ: LEGN) launched a $225M public offering of ADSs, each representing two ordinary shares.
- Underwriters have a 30-day option to purchase an additional 15% of ADSs at the public offering price.
- The offering is subject to market conditions and no assurances are given on completion terms.
- Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are joint book-running managers.
- Proceeds may support expansion of CARVYKTI®, Legend Biotech’s CAR-T cell therapy for multiple myeloma.
The big picture
Legend Biotech’s $225M ADS offering reflects its strategic push to solidify dominance in cell therapy, particularly with CARVYKTI®. The move comes as the biotech sector faces increasing competition and regulatory scrutiny, with capital raises becoming critical for scaling innovative treatments. The involvement of top-tier underwriters underscores the deal’s significance in the broader biotech financing landscape.
What we're watching
- Market Conditions
- Whether volatile market conditions will impact the completion or terms of the offering.
- Execution Risk
- How Legend Biotech will deploy proceeds to maximize CARVYKTI’s patient access and therapeutic potential.
- Competitive Dynamics
- The pace at which Legend Biotech can sustain leadership in the CAR-T cell therapy space amid rising competition.
Related topics